Danziten — CareFirst (Caremark)

Initial criteria

• Disease is metastatic or unresectable
• Tumor has c-KIT activating mutations
• Medication will be used as subsequent therapy
• Member has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy
• Medication will be used as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

Initial and continuation 12 months